Nuveen
LCTX icon

Nuveen’s Lineage Cell Therapeutics LCTX Stock Holding History

Nuveen’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$321K Buy
+245,384
New +$339K ﹤0.01% 3475
2025
Q2 		– Sell
-515,445
Closed -$233K – 3338
2025
Q1 		$233K Hold
515,445
– – ﹤0.01% 3094
2024
Q4 		$259K Hold
515,445
– – ﹤0.01% 3157
2024
Q3 		$467K Hold
515,445
– – ﹤0.01% 3038
2024
Q2 		$514K Hold
515,445
– – ﹤0.01% 2983
2024
Q1 		$763K Hold
515,445
– – ﹤0.01% 2810
2023
Q4 		$562K Hold
515,445
– – ﹤0.01% 2968
2023
Q3 		$608K Hold
515,445
– – ﹤0.01% 2778
2023
Q2 		$727K Buy
+515,445
New +$712K ﹤0.01% 2798
2022
Q2 		– Sell
-551,993
Closed -$750K – 3383
2022
Q1 		$750K Buy
551,993
+145,063
+36% +$225K ﹤0.01% 2906
2021
Q4 		$745K Sell
406,930
-34,661
-8% -$81.1K ﹤0.01% 2955
2021
Q3 		$1.13M Sell
441,591
-8,320
-2% -$21.3K ﹤0.01% 2952
2021
Q2 		$1.28M Buy
+449,911
New +$1.16M ﹤0.01% 2913
2020
Q2 		– Sell
-423,265
Closed -$350K – 3320
2020
Q1 		$350K Sell
423,265
-66,546
-14% -$66.3K ﹤0.01% 2895
2019
Q4 		$435K Sell
489,811
-580,940
-54% -$484K ﹤0.01% 2936
2019
Q3 		$1.05M Buy
1,070,751
+72,602
+7% +$75.2K ﹤0.01% 2686
2019
Q2 		$1.1M Buy
+998,149
New +$1.15M ﹤0.01% 2698

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Nuveen's LCTX Position: Q2 2026 in Review

Nuveen opened a new position in Lineage Cell Therapeutics (LCTX) in Q2 2026: 245,384 shares worth $321K. The stake represents ﹤0.01% of the portfolio and ranks #3475 among its holdings. This is a return to the name: Nuveen previously reported a position in LCTX as recently as Q1 2025.

Nuveen first reported a position in LCTX in Q2 2019 and has held it in 17 quarters since. The position peaked at $1.28M in Q2 2021. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Nuveen held 245,384 shares of Lineage Cell Therapeutics worth $321K as of Q2 2026.
  • Lineage Cell Therapeutics was a new Nuveen position in Q2 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3475 holding.
  • Nuveen first reported a position in Lineage Cell Therapeutics in Q2 2019 and has held it in 17 quarters since.
  • Nuveen's Lineage Cell Therapeutics position peaked at $1.28M in Q2 2021.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.